MA50541A - Formulations pharmaceutiques - Google Patents

Formulations pharmaceutiques

Info

Publication number: MA50541A
Authority: MA; Morocco
Prior art keywords: pharmaceutical formulations; formulations; pharmaceutical
Prior art date: 2015-06-30

Application number

MA050541A

Other languages

English (en)

Inventor

Joanna M Koziara

Scott Mccallister

Original Assignee

Gilead Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-06-30

Filing date

2016-06-29

Publication date

2021-04-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56418608&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50541(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-06-29 Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc

2021-04-07 Publication of MA50541A publication Critical patent/MA50541A/fr

Links

239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

MA050541A 2015-06-30 2016-06-29 Formulations pharmaceutiques MA50541A (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US201562187113P	2015-06-30	2015-06-30
US201662298373P	2016-02-22	2016-02-22
US201662301429P	2016-02-29	2016-02-29
US201662317286P	2016-04-01	2016-04-01

Publications (1)

Publication Number	Publication Date
MA50541A true MA50541A (fr)	2021-04-07

Family

ID=56418608

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA050541A MA50541A (fr)	2015-06-30	2016-06-29	Formulations pharmaceutiques

Country Status (26)

Country	Link
US (2)	US20170000807A1 (fr)
EP (5)	EP4233846A3 (fr)
JP (3)	JP6667556B2 (fr)
KR (2)	KR102313668B1 (fr)
CN (1)	CN107847450A (fr)
AU (3)	AU2016287500B2 (fr)
BR (1)	BR112017027843A2 (fr)
CA (1)	CA2990210C (fr)
CL (1)	CL2017003320A1 (fr)
CO (1)	CO2017013293A2 (fr)
CU (1)	CU20170168A7 (fr)
DO (1)	DOP2017000306A (fr)
EA (1)	EA201792592A1 (fr)
EC (1)	ECSP17084331A (fr)
ES (4)	ES2945345T3 (fr)
HK (1)	HK1248547A1 (fr)
IL (1)	IL256364A (fr)
MA (1)	MA50541A (fr)
MX (1)	MX2017016806A (fr)
PE (1)	PE20180411A1 (fr)
PH (1)	PH12017502431A1 (fr)
PL (4)	PL3607939T3 (fr)
PT (4)	PT4070788T (fr)
SI (4)	SI4070787T1 (fr)
SV (1)	SV2017005601A (fr)
WO (1)	WO2017004244A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9216996B2 (en)	2012-12-21	2015-12-22	Gilead Sciences, Inc.	Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections
DK3236972T3 (en)	2014-12-26	2021-10-04	Univ Emory	Antivirale N4-hydroxycytidin-derivativer
SI3346995T1 (sl)	2015-11-09	2019-11-29	Gilead Sciences Inc	Terapevtski sestavek za zdravljenje virusa človeške imunske pomanjkljivosti
MX2019009764A (es)	2017-02-17	2019-11-11	Eidos Therapeutics Inc	Procesos para preparar acido 3-(3-(3,5-dimetil-1h-pirazol-4-il)pro poxi)-4- 5-fluorobenzoico (ag-10), sus compuestos intermedios, y sales del mismo.
WO2018153977A1 (fr) *	2017-02-24	2018-08-30	Hexal Ag	Composition stable de ténofovir alafénamide
US11191763B2 (en)	2017-03-20	2021-12-07	The United States Of America As Represented By The Secretary, Department Of Health And Human Services	HIV post-exposure prophylaxis
RU2662160C9 (ru)	2017-07-03	2018-10-22	Александрович Иващенко Андрей	Комбинированный лекарственный препарат для терапии вирусных инфекций
SG11202004403QA (en)	2017-12-07	2020-06-29	Univ Emory	N4-hydroxycytidine and derivatives and anti-viral uses related thereto
BR112020026493A2 (pt) *	2018-08-17	2021-03-23	Eidos Therapeutics, Inc.	Formulações de ag10
CN111096954B (zh) *	2018-10-29	2022-09-16	江苏豪森药业集团有限公司	一种用于抗病毒感染的药物组合物及制备方法
CN110251476B (zh) *	2019-08-01	2022-08-09	海思科制药(眉山)有限公司	一种恩曲他滨替诺福韦药物组合物
CN110917197A (zh) *	2019-12-31	2020-03-27	常州恒邦药业有限公司	一种替诺福韦酯与恩曲他滨的药物组合物及其制备方法
TWI728709B (zh) *	2020-02-19	2021-05-21	台灣森本生物科技開發股份有限公司	含有得自於藤黃樹脂的丙酮萃取產物的藥學組成物以及由該組成物所製得的配方

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ304734B6 (cs)	2000-07-21	2014-09-10	Gilead Sciences, Inc.	Způsob přípravy 9-[2-(fosfonomethoxy)propyl]adeninu a 9-[2-(fosfonomethoxy)ethyl]adeninu
JO3429B1 (ar)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
EP1923063A3 (fr) *	2003-01-14	2009-04-08	Gilead Sciences, Inc.	Compositions et procédés pour une thérapie antivirale combinée
TWI375560B (en)	2005-06-13	2012-11-01	Gilead Sciences Inc	Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) *	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	單一式藥學劑量型
SG173544A1 (en)	2009-02-06	2011-09-29	Gilead Sciences Inc	Tablets for combination therapy
CA2845553C (fr)	2011-08-16	2019-05-28	Gilead Sciences, Inc.	Hemifumarate de tenofovir alafenamide
EA026138B1 (ru) *	2012-02-03	2017-03-31	Джилид Сайэнс, Инк.	Комбинированная терапия, включающая тенофовир алафенамида гемифумарат и кобицистат, для применения для лечения вирусных инфекций
JP2016528240A (ja) *	2013-08-14	2016-09-15	ラシオファルムゲーエムベーハー	ドルテグラビル、エムトリシタビン及びテノホビルの医薬コンビネーションを有する医薬
CZ2013985A3 (cs) *	2013-12-09	2015-06-17	Zentiva, K.S.	Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
NO2717902T3 (fr) *	2014-06-20	2018-06-23

2016
- 2016-06-29 US US15/197,491 patent/US20170000807A1/en not_active Abandoned
- 2016-06-29 PE PE2017002785A patent/PE20180411A1/es unknown
- 2016-06-29 ES ES22176524T patent/ES2945345T3/es active Active
- 2016-06-29 CA CA2990210A patent/CA2990210C/fr active Active
- 2016-06-29 CN CN201680045136.1A patent/CN107847450A/zh active Pending
- 2016-06-29 PT PT221765373T patent/PT4070788T/pt unknown
- 2016-06-29 EP EP23162978.3A patent/EP4233846A3/fr active Pending
- 2016-06-29 EP EP19199257.7A patent/EP3607939B1/fr active Active
- 2016-06-29 MA MA050541A patent/MA50541A/fr unknown
- 2016-06-29 PT PT221765241T patent/PT4070787T/pt unknown
- 2016-06-29 EP EP22176524.1A patent/EP4070787B1/fr active Active
- 2016-06-29 SI SI201631707T patent/SI4070787T1/sl unknown
- 2016-06-29 ES ES16739625T patent/ES2786549T3/es active Active
- 2016-06-29 EP EP16739625.8A patent/EP3316868B1/fr active Active
- 2016-06-29 EP EP22176537.3A patent/EP4070788B1/fr active Active
- 2016-06-29 SI SI201630656T patent/SI3316868T1/sl unknown
- 2016-06-29 PL PL19199257.7T patent/PL3607939T3/pl unknown
- 2016-06-29 KR KR1020207016036A patent/KR102313668B1/ko active IP Right Grant
- 2016-06-29 US US15/738,067 patent/US20180177734A1/en not_active Abandoned
- 2016-06-29 BR BR112017027843-0A patent/BR112017027843A2/pt not_active Application Discontinuation
- 2016-06-29 EA EA201792592A patent/EA201792592A1/ru unknown
- 2016-06-29 KR KR1020187002382A patent/KR102121329B1/ko active IP Right Grant
- 2016-06-29 PT PT191992577T patent/PT3607939T/pt unknown
- 2016-06-29 PL PL16739625T patent/PL3316868T3/pl unknown
- 2016-06-29 MX MX2017016806A patent/MX2017016806A/es unknown
- 2016-06-29 ES ES22176537T patent/ES2945896T3/es active Active
- 2016-06-29 PL PL22176537.3T patent/PL4070788T3/pl unknown
- 2016-06-29 WO PCT/US2016/040158 patent/WO2017004244A1/fr active Application Filing
- 2016-06-29 ES ES19199257T patent/ES2925246T3/es active Active
- 2016-06-29 PL PL22176524.1T patent/PL4070787T3/pl unknown
- 2016-06-29 CU CUP2017000168A patent/CU20170168A7/xx unknown
- 2016-06-29 SI SI201631702T patent/SI4070788T1/sl unknown
- 2016-06-29 PT PT167396258T patent/PT3316868T/pt unknown
- 2016-06-29 JP JP2017566409A patent/JP6667556B2/ja active Active
- 2016-06-29 SI SI201631582T patent/SI3607939T1/sl unknown
- 2016-06-29 AU AU2016287500A patent/AU2016287500B2/en active Active
2017
- 2017-12-17 IL IL256364A patent/IL256364A/en unknown
- 2017-12-21 EC ECIEPI201784331A patent/ECSP17084331A/es unknown
- 2017-12-21 CL CL2017003320A patent/CL2017003320A1/es unknown
- 2017-12-21 DO DO2017000306A patent/DOP2017000306A/es unknown
- 2017-12-21 SV SV2017005601A patent/SV2017005601A/es unknown
- 2017-12-21 CO CONC2017/0013293A patent/CO2017013293A2/es unknown
- 2017-12-22 PH PH12017502431A patent/PH12017502431A1/en unknown
2018
- 2018-06-27 HK HK18108248.3A patent/HK1248547A1/zh unknown
2019
- 2019-07-31 AU AU2019210558A patent/AU2019210558B2/en active Active
2020
- 2020-02-25 JP JP2020029330A patent/JP6978534B2/ja active Active
2021
- 2021-03-31 AU AU2021202009A patent/AU2021202009B2/en active Active
- 2021-09-01 JP JP2021142184A patent/JP2021185188A/ja active Pending

Also Published As

Publication number	Publication date
ECSP17084331A (es)	2018-01-31
SI4070787T1 (sl)	2023-07-31
AU2021202009A1 (en)	2021-04-29
AU2016287500B2 (en)	2019-05-02
JP2020079304A (ja)	2020-05-28
EP3607939B1 (fr)	2022-06-01
PL3607939T3 (pl)	2022-11-07
PE20180411A1 (es)	2018-03-01
ES2786549T3 (es)	2020-10-13
CL2017003320A1 (es)	2018-07-13
IL256364A (en)	2018-02-28
PL4070787T3 (pl)	2023-07-24
ES2945896T3 (es)	2023-07-10
PT4070787T (pt)	2023-05-22
AU2019210558A1 (en)	2019-08-15
ES2945345T3 (es)	2023-06-30
US20180177734A1 (en)	2018-06-28
US20170000807A1 (en)	2017-01-05
ES2925246T3 (es)	2022-10-14
EP4233846A3 (fr)	2023-10-04
EP4070788B1 (fr)	2023-03-22
SI3316868T1 (sl)	2020-04-30
WO2017004244A1 (fr)	2017-01-05
PL4070788T3 (pl)	2023-07-10
JP2018519297A (ja)	2018-07-19
EA201792592A1 (ru)	2018-06-29
AU2016287500A1 (en)	2018-01-18
EP4233846A2 (fr)	2023-08-30
MX2017016806A (es)	2018-05-07
DOP2017000306A (es)	2018-01-15
EP3316868B1 (fr)	2020-02-19
SI3607939T1 (sl)	2022-10-28
CN107847450A (zh)	2018-03-27
CA2990210A1 (fr)	2017-01-05
AU2021202009B2 (en)	2023-04-13
PT3607939T (pt)	2022-09-12
JP6978534B2 (ja)	2021-12-08
AU2019210558B2 (en)	2021-04-22
KR20180021134A (ko)	2018-02-28
SV2017005601A (es)	2018-05-04
JP6667556B2 (ja)	2020-03-18
HK1248547A1 (zh)	2018-10-19
EP4070788A1 (fr)	2022-10-12
CU20170168A7 (es)	2018-07-05
KR102313668B1 (ko)	2021-10-19
CO2017013293A2 (es)	2018-05-31
KR102121329B1 (ko)	2020-06-17
CA2990210C (fr)	2021-01-12
EP4070787B1 (fr)	2023-03-01
PH12017502431A1 (en)	2018-07-02
PT3316868T (pt)	2020-04-21
EP3607939A1 (fr)	2020-02-12
KR20200067937A (ko)	2020-06-12
BR112017027843A2 (pt)	2018-09-04
PT4070788T (pt)	2023-06-06
PL3316868T3 (pl)	2020-10-19
EP4070787A1 (fr)	2022-10-12
JP2021185188A (ja)	2021-12-09
SI4070788T1 (sl)	2023-06-30
EP3316868A1 (fr)	2018-05-09

Publication	Publication Date	Title
DK3529248T3 (da)	2020-09-14	Farmaceutiske sammensætninger
MA50541A (fr)	2021-04-07	Formulations pharmaceutiques
DK3089741T3 (da)	2021-06-07	Farmaceutiske sammensætninger omfattende azd9291
MA42303A (fr)	2018-05-09	Formulations pharmaceutiques
MA46867A (fr)	2019-09-25	Formulations pharmaceutiques
MA54716A (fr)	2021-11-17	Réduction de la viscosité de formulations pharmaceutiques
DK3634377T3 (da)	2021-08-30	Farmaceutisk formulering
DK3199161T3 (da)	2022-01-03	Farmaceutisk præparat
MA45187A (fr)	2019-04-10	Combinaisons pharmaceutiques
MA44987A (fr)	2019-03-20	Formulations de médicaments améliorées
ES2841649T5 (es)	2024-04-24	Composición farmacéutica
MA49837A (fr)	2020-06-17	Compositions pharmaceutiques
DK3191085T3 (da)	2021-06-28	Misbrugsresistente farmaceutiske sammensætninger
ZA201707094B (en)	2021-04-28	Pharmaceutical formulations
DK3601277T3 (da)	2024-01-15	Farmaceutisk formulering
DK3313370T3 (da)	2021-03-29	Oftalmologisk farmaceutisk sammensætning
DK3288967T3 (da)	2020-02-10	Farmaceutisk forbindelse
DK3256138T3 (da)	2022-05-16	Farmaceutiske sammensætninger omfattende meloxicam
TR201503831A2 (tr)	2016-10-21	Antimipertansif kombinasyon formülasyonları
DK3089740T3 (da)	2020-08-03	Farmaceutisk sammensætning
MA49625A (fr)	2020-05-27	Compositions pharmaceutiques
DK3481370T3 (da)	2021-06-07	Farmaceutisk sammensætning omfattende benzydamin
DK3558261T3 (da)	2022-06-20	Farmaceutiske sammensætninger omfattende safinamid
MA42111A (fr)	2018-03-28	Compositions pharmaceutiques topiques
DK3288966T3 (da)	2020-02-10	Farmaceutisk forbindelse